Top

BMC Ophthalmology

Published in:

Open Access 01-12-2007 | Case report

Thiazolidinedione induced thyroid associated orbitopathy

Authors: Seongmu Lee, Angelo Tsirbas, Robert A Goldberg, John D McCann

Published in: BMC Ophthalmology | Issue 1/2007

Abstract

Background

To describe an episode of thyroid associated orbitopathy (TAO) following the initiation of thiazolidinedione (TZD).

Case presentation

We report a female patient with a history of Graves' disease and stabilised thyroid associated orbitopathy for 2.5 years, who experienced rapid progression of TAO after the initiation of thiazolidinedione for glycemic control. Following the discontinuation of TZD, the patient experienced subsequent stabilisation of disease and normalization of vision. The medical history, ophthalmic findings, and clinical course are discussed.

Conclusion

Thiazolidinediones may exacerbate TAO, and this should be taken into consideration when selecting treatment for diabetic patients with a history of autoimmune thyroid disorders.

Available only for authorised users

Yki-Järvinen H: Drug Therapy: Thiazolidinediones. N Engl J Med. 351 (11): 1106-18. 10.1056/NEJMra041001. 2004 Sep 9;

Bartley GB: The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994, 92: 477-588.PubMedPubMedCentral

Bartalena L, Marcocci C, Bogazzi F, Hegedus L: Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 338 (2): 73-8. 10.1056/NEJM199801083380201. 1998 Jan 8;

Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A: Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 326 (26): 1733-8. 1992 Jun 25;

Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D: Smoking and thyroid associated ophthalmopathy; a novel explanation of the biological link. J Clin Endocrinol Metab. 2006 Oct 17;,

Kumar S, Coenen MJ, Scherer PE, Bahn RS: Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2004, 89 (2): 930-5. 10.1210/jc.2003-031427.CrossRefPubMedPubMedCentral

Valyasevi RW, Harteneck DA, Dutton CM, Bahn RS: Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab. 2002, 87 (5): 2352-8. 10.1210/jc.87.5.2352.PubMed

Pasquali D, Pierantoni GM, Fusco A, Staibano S, Colantuoni V, DeBellis A, Bellastella A, Sinisi AA: Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol. 2004, 33 (1): 133-43. 10.1677/jme.0.0330133.CrossRefPubMed

Pistrosch F, Herbrig K, Oelschlaegel U, Richter S, Passauer J, Fischer S, Gross P: PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells. Atherosclerosis. 2005, 183 (1): 163-7. 10.1016/j.atherosclerosis.2005.03.039.CrossRefPubMed

10.

Mimura LY, Villares SM, Monteiro ML, Guazzelli IC, Bloise W: Peroxisome proliferator-activated receptor-gamma gene expression in orbital adipose/connective tissues is increased during the active stage of Graves' ophthalmopathy. Thyroid. 2003, 13 (9): 845-50. 10.1089/105072503322401032.CrossRefPubMed

11.

Wakelkamp I, Bakker O, Baldeschi L, Wiersinga WM, Prummel MF: TSH-R expression and cytokine profile in orbital tissue of active vs inactive Graves' ophthalmopathy patients. Clin Endocrinol. 2003, 58: 280-287. 10.1046/j.1365-2265.2003.01708.x.CrossRef

12.

Starkey K, Heufelder A, Baker G, Joba W, Evans M, Davies S, Ludgate M: Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?. J Clin Endocrinol Metab. 2003, 88: 55-9. 10.1210/jc.2002-020987.CrossRefPubMed

13.

Levin F, Kazim M, Smith TJ, Marcovici E: Rosiglitazone-induced proptosis. Arch Ophthalmol. 2005, 123: 119-21. 10.1001/archopht.123.1.119.CrossRefPubMed

14.

Dorkhan M, Lantz M, Frid A, Groop L, Hallengren B: Treatment with a thiazolidinedione increases eye protrusion in a subgroup of patients with type 2 diabetes. Clin Endocrinol (Oxf). 2006, 65: 35-9. 10.1111/j.1365-2265.2006.02542.x.CrossRef

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/7/8/prepub

Title: Thiazolidinedione induced thyroid associated orbitopathy
Authors: Seongmu Lee
Angelo Tsirbas
Robert A Goldberg
John D McCann
Publication date: 01-12-2007
Publisher: BioMed Central
Published in: BMC Ophthalmology / Issue 1/2007
Electronic ISSN: 1471-2415
DOI: https://doi.org/10.1186/1471-2415-7-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Thiazolidinedione induced thyroid associated orbitopathy

Abstract

Background

Case presentation

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2007

Prevalence of diabetic retinopathy in the United Arab Emirates: a cross-sectional survey

Molecular characterization, biofilm analysis and experimental biofouling study of Fusariumisolates from recent cases of fungal keratitis in New York State

Unilateral external ophthalmoplegia in Miller Fisher syndrome: case report

TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD

A decade of clinical negligence in ophthalmology

Establishing the tolerability and performance of tamarind seed polysaccharide (TSP) in treating dry eye syndrome: results of a clinical study